MRTX Key Statistics, Chart & Performance
The current stock price of MRTX is 58.7 USD. In the past month the price decreased by -0.44%. In the past year, price increased by 10.57%.
MRTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MRTX. When comparing the yearly performance of all stocks, MRTX turns out to be only a medium performer in the overall market: it outperformed 69.11% of all stocks.
MRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MRTX. No worries on liquidiy or solvency for MRTX as it has an excellent financial health rating, but there are worries on the profitability.
MRTX Financial Highlights
Over the last trailing twelve months MRTX reported a non-GAAP Earnings per Share(EPS) of -12.22. The EPS increased by 8.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| Debt/Equity | 0 |
MRTX Forecast & Estimates
22 analysts have analysed MRTX and the average price target is 62.42 USD. This implies a price increase of 6.34% is expected in the next year compared to the current price of 58.7.
For the next year, analysts expect an EPS growth of 14.07% and a revenue growth 406.04% for MRTX
MRTX Ownership
MRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.65 | 378.29B | ||
| AMGN | AMGEN INC | 15.13 | 178.24B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.02B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.47 | 112.16B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 77.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 697.12 | 46.97B | ||
| INSM | INSMED INC | N/A | 34.87B | ||
| NTRA | NATERA INC | N/A | 32.41B | ||
| BIIB | BIOGEN INC | 9.88 | 24.26B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.47B | ||
| INCY | INCYTE CORP | 15.98 | 20.15B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.74 | 20.16B |
Related stock screener links
About MRTX
Company Profile
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Company Info
MIRATI THERAPEUTICS INC
3545 Cray Court
San Diego CALIFORNIA 92121 US
CEO: Charles M. Baum
Employees: 587
Phone: 18583323410
MIRATI THERAPEUTICS INC / MRTX FAQ
What does MRTX do?
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
What is the current price of MRTX stock?
The current stock price of MRTX is 58.7 USD. The price decreased by -0.17% in the last trading session.
What is the dividend status of MIRATI THERAPEUTICS INC?
MRTX does not pay a dividend.
How is the ChartMill rating for MIRATI THERAPEUTICS INC?
MRTX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for MIRATI THERAPEUTICS INC?
MIRATI THERAPEUTICS INC (MRTX) operates in the Health Care sector and the Biotechnology industry.
Would investing in MIRATI THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MRTX.
Can you provide the ownership details for MRTX stock?
You can find the ownership structure of MIRATI THERAPEUTICS INC (MRTX) on the Ownership tab.